Investors sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading on Thursday. $117.62 million flowed into the stock on the tick-up and $147.72 million flowed out of the stock on the tick-down, for a money net flow of $30.10 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.67 for the day and closed at $79.57

Several equities research analysts recently issued reports on GILD shares. Barclays PLC reaffirmed an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $107.61 price objective for the company in a research note on Tuesday, April 26th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Finally, RBC Capital Markets set a $105.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday. Ten analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $107.37.

The company’s 50-day moving average price is $83.15 and its 200-day moving average price is $87.70. The stock has a market cap of $104.53 billion and a PE ratio of 6.95.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.15 EPS. Equities research analysts predict that Gilead Sciences Inc. will post $11.77 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date of this dividend is Wednesday, September 14th.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $79.81, for a total value of $159,620.00. Following the transaction, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at approximately $5,117,576.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $86.94, for a total transaction of $9,737,280.00. Following the completion of the transaction, the chief executive officer now directly owns 1,170,963 shares in the company, valued at $101,803,523.22. The disclosure for this sale can be found here.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Gilead Sciences by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 85,547,536 shares of the biopharmaceutical company’s stock valued at $8,656,555,000 after buying an additional 596,921 shares in the last quarter. Morgan Stanley raised its position in Gilead Sciences by 18.0% in the fourth quarter. Morgan Stanley now owns 10,614,126 shares of the biopharmaceutical company’s stock valued at $1,074,043,000 after buying an additional 1,616,773 shares in the last quarter. OppenheimerFunds Inc. raised its position in Gilead Sciences by 14.2% in the fourth quarter. OppenheimerFunds Inc. now owns 9,261,694 shares of the biopharmaceutical company’s stock valued at $937,207,000 after buying an additional 1,153,162 shares in the last quarter. Agran Libbie raised its position in Gilead Sciences by 10,050.3% in the fourth quarter. Agran Libbie now owns 9,001,584 shares of the biopharmaceutical company’s stock valued at $9,109,000 after buying an additional 8,912,901 shares in the last quarter. Finally, Boston Partners raised its position in Gilead Sciences by 1.4% in the fourth quarter. Boston Partners now owns 6,843,182 shares of the biopharmaceutical company’s stock valued at $692,462,000 after buying an additional 93,588 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.